Payment overview · 2025
General Payments
$95.33
5 reported records · 3 companies
Healthcare provider profile · identity verified
Mohammed Jaleel, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · WINCHESTER, MA · NPI 1568425346
Verified facts
What the public records show
CMS Open Payments records show Mohammed Jaleel, M.D. received $95.33 in general payments during 2025 across 5 reported records.
Novartis Pharmaceuticals Corporation accounted for 58.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 783 claims for Eliquis by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Nuedexta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $56.07 | 58.8% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $21.40 | 22.4% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $17.86 | 18.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $95.33 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $56.07 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $21.40 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $17.86 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 783 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
783 | 48 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 2015 | 154 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1073 | 76 |
| Trazodone Hcl | Trazodone Hcl | 1027 | 54 |
| Gabapentin | Gabapentin | 995 | 52 |
| Furosemide | Furosemide | 889 | 71 |
| Metoprolol Succinate | Metoprolol Succinate | 871 | 85 |
| Eliquis | Apixaban | 783 | 48 |
| Amlodipine Besylate | Amlodipine Besylate | 746 | 93 |
| Sertraline Hcl | Sertraline Hcl | 662 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 626 | 46 |
| Omeprazole | Omeprazole | 580 | 51 |
| Pantoprazole Sodium | Pantoprazole Sodium | 548 | 41 |
| Potassium Chloride | Potassium Chloride | 500 | 35 |
| Lisinopril | Lisinopril | 460 | 70 |
| Losartan Potassium | Losartan Potassium | 455 | 51 |
| Metformin Hcl | Metformin Hcl | 443 | 44 |
| Donepezil Hcl | Donepezil Hcl | 405 | 20 |
| Mirtazapine | Mirtazapine | 400 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 383 | 19 |
| Simvastatin | Simvastatin | 357 | 33 |
| Tamsulosin Hcl | Tamsulosin Hcl | 341 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 326 | 24 |
| Torsemide | Torsemide | 300 | 19 |
| Warfarin Sodium | Warfarin Sodium | 276 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 274 | 20 |
| Spironolactone | Spironolactone | 270 | 22 |
| Atenolol | Atenolol | 241 | 25 |
| Ezetimibe | Ezetimibe | 237 | 12 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 221 | 42 |
| Quetiapine Fumarate | Quetiapine Fumarate | 205 | 23 |
| Allopurinol | Allopurinol | 198 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 178 | 14 |
| Levetiracetam | Levetiracetam | 176 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 169 | suppressed |
| Memantine Hcl | Memantine Hcl | 157 | 11 |
| Amiodarone Hcl | Amiodarone Hcl | 156 | suppressed |
| Xarelto | Rivaroxaban | 155 | suppressed |
| Glipizide | Glipizide | 154 | 11 |
| Hydrochlorothiazide | Hydrochlorothiazide | 152 | 38 |
| Divalproex Sodium | Divalproex Sodium | 139 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 138 | 34 |
| Baclofen | Baclofen | 136 | suppressed |
| Prednisone | Prednisone | 130 | 39 |
| Januvia | Sitagliptin Phosphate | 126 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 114 | suppressed |
| Bumetanide | Bumetanide | 109 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 109 | suppressed |
| Olanzapine | Olanzapine | 106 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 99 | suppressed |
| Famotidine | Famotidine | 93 | 14 |
| Buspirone Hcl | Buspirone Hcl | 87 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 87 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 85 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 83 | 35 |
| Folic Acid | Folic Acid | 83 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 83 | suppressed |
| Irbesartan | Irbesartan | 82 | suppressed |
| Digoxin | Digoxin | 81 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 78 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 72 | suppressed |
| Meloxicam | Meloxicam | 70 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 68 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 67 | suppressed |
| Lorazepam | Lorazepam | 66 | 12 |
| Carvedilol | Carvedilol | 65 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 62 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 62 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 62 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 58 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 56 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 55 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 55 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 54 | 26 |
| Trospium Chloride | Trospium Chloride | 53 | suppressed |
| Carbamazepine | Carbamazepine | 51 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 51 | 15 |
| Midodrine Hcl | Midodrine Hcl | 51 | suppressed |
| Myrbetriq | Mirabegron | 51 | suppressed |
| Trospium Chloride Er | Trospium Chloride | 51 | suppressed |
| Aripiprazole | Aripiprazole | 50 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 50 | suppressed |
| Valsartan | Valsartan | 47 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 46 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 46 | 12 |
| Bethanechol Chloride | Bethanechol Chloride | 44 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 44 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 44 | suppressed |
| Leflunomide | Leflunomide | 43 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 41 | 16 |
| Terazosin Hcl | Terazosin Hcl | 41 | suppressed |
| Chlorthalidone | Chlorthalidone | 40 | suppressed |
| Febuxostat | Febuxostat | 40 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 39 | suppressed |
| Jardiance | Empagliflozin | 39 | suppressed |
| Finasteride | Finasteride | 38 | suppressed |
| Latanoprost | Latanoprost | 38 | suppressed |
| Clonazepam | Clonazepam | 37 | suppressed |
| Fenofibrate | Fenofibrate | 37 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 37 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 33 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 33 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 32 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 32 | 12 |
| Tradjenta | Linagliptin | 32 | suppressed |
| Acetic Acid | Acetic Acid | 31 | suppressed |
| Gemtesa | Vibegron | 31 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 30 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 30 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 30 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 30 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 29 | suppressed |
| Alprazolam | Alprazolam | 28 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 28 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 27 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 27 | suppressed |
| Celecoxib | Celecoxib | 26 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 25 | 21 |
| Flecainide Acetate | Flecainide Acetate | 25 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 25 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 25 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 24 | 17 |
| Ondansetron Hcl | Ondansetron Hcl | 24 | 15 |
| Timolol Maleate | Timolol Maleate | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 18 |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 22 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 21 | suppressed |
| Mupirocin | Mupirocin | 21 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Verapamil Er | Verapamil Hcl | 20 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 16 |
| Labetalol Hcl | Labetalol Hcl | 19 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 18 | 11 |
| Erythromycin | Erythromycin Base | 17 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 17 | suppressed |
| Mounjaro | Tirzepatide | 17 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 17 | suppressed |
| Ramelteon | Ramelteon | 17 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Insulin Lispro | Insulin Lispro | 16 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Heparin Sodium | Heparin Sodium,porcine | 15 | suppressed |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 14 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 14 | suppressed |
| Benzonatate | Benzonatate | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Xifaxan | Rifaximin | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Droxidopa | Droxidopa | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Serevent Diskus | Salmeterol Xinafoate | 11 | suppressed |
| Sulfasalazine Dr | Sulfasalazine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $95.33 · 5 records | Novartis Pharmaceuticals Corporation | ELIQUIS, LEQVIO, REXULTI | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error